Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vistagen

< Previous 1 2 Next >
Vistagen to Present at Stifel 2023 Healthcare Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Appoints Cindy Anderson as Chief Financial Officer
From Vistagen
Via Business Wire
Tickers VTGN
Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Regains Full Compliance with Nasdaq Listing Requirements
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Stockholder-Approved Reverse Stock Split
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Receives New European Patent for AV-101
From Vistagen
Via Business Wire
Tickers VTGN
FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
From Vistagen
Via Business Wire
Tickers VTGN
Vistagen to Present at Cowen 43rd Annual Health Care Conference
From Vistagen
Via Business Wire
Tickers VTGN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.